Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
51
AAVXF Quote, Financials, Valuation and Earnings
Last price:
$125.66
Seasonality move
:
34.91%
Day range:
$125.66 - $125.66
52-week range:
$5.81 - $133.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
16.54x
Volume:
--
Avg. volume:
36
1-year change:
2033.38%
Market cap:
$9.9B
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Abivax SA has -- downside to fair value with a price target of -- per share.
AAVXF vs. S&P 500
-
Over the past 5 trading days, Abivax SA has overperformed the S&P 500 by 0.45% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Abivax SA does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Abivax SA has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Abivax SA reported revenues of --.
Earnings Growth
-
Abivax SA has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Abivax SA reported earnings per share of -$2.46.
Enterprise value:
9.3B
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-55.68x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -$317.9K | |
| Operating Income | -- | -- | -- | -- | -$96.7M | |
| EBITDA | -- | -- | -- | -- | -$96.4M | |
| Diluted EPS | -- | -- | -- | -- | -$2.46 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | -- | $727.7M | |
| Total Assets | -- | -- | -- | -- | $766.2M | |
| Current Liabilities | -- | -- | -- | -- | $92.5M | |
| Total Liabilities | -- | -- | -- | -- | $165.5M | |
| Total Equity | -- | -- | -- | -- | $600.7M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -$83.5M | |
| Cash From Investing | -- | -- | -- | -- | -$202.5K | |
| Cash From Financing | -- | -- | -- | -- | $706.6M | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
AAVXF
Sector
Market Cap
$9.9B
$25.5M
Price % of 52-Week High
94.2%
50%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.62%
1-Year Price Total Return
2033.38%
-18.12%
Beta (5-Year)
1.242
0.490
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$125.66
200-day SMA
Buy
Level
$77.06
Bollinger Bands (100)
Buy
Level
99.8 - 124.44
Chaikin Money Flow
Sell
Level
-71.7K
20-day SMA
Buy
Level
$122.77
Relative Strength Index (RSI14)
Buy
Level
74.62
ADX Line
Buy
Level
35.69
Williams %R
Sell
Level
0
50-day SMA
Buy
Level
$121.20
MACD (12, 26)
Buy
Level
1.57
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
25.3K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.0172)
Sell
CA Score
(Annual)
Level (-3.8445)
--
Beneish M-Score
(Annual)
Level (--)
--
Momentum Score
Level (--)
Sell
Ohlson Score
Level (6.2241)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.
Stock Forecast FAQ
In the current month, AAVXF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AAVXF average analyst price target in the past 3 months is --.
-
Where Will Abivax SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that Abivax SA share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Abivax SA?
Analysts are divided on their view about Abivax SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Abivax SA is a Sell and believe this share price will rise from its current level to --.
-
What Is Abivax SA's Price Target?
The price target for Abivax SA over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AAVXF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Abivax SA is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of AAVXF?
You can purchase shares of Abivax SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Abivax SA shares.
-
What Is The Abivax SA Share Price Today?
Abivax SA was last trading at $125.66 per share. This represents the most recent stock quote for Abivax SA. Yesterday, Abivax SA closed at $125.66 per share.
-
How To Buy Abivax SA Stock Online?
In order to purchase Abivax SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get AAVXF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
AAVXF
Sector
P/E ratio
--
23.08x
PEG ratio
--
-0.01x
P/B ratio
16.54x
1.81x
Price / LTM sales
--
1.54x
Growth Metrics
AAVXF
Sector
Revenue growth
--
3.44%
Earnings growth
--
11.11%
Revenue (5-year growth)
--
6.46%
Earnings forecast
--
-$0.19
Profitability
AAVXF
Sector
Profitability FY 2024
-$1.2M
$2.4M
Return on invested capital
--
-33.43%
Return on assets
--
-29.79%
Return on equity
--
-39.31%
Earnings Date
Last Earnings Date
Sep
8
Next Earnings Date
Mar
23
Estimated Next Earnings Date
Dec
8
Balance Sheet
AAVXF
Sector
Total cash
$692.9M
$24.1M
Short term investments
--
$23.8M
Total assets
$212.5M
$70.2M
Long term debt
--
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
AAOI alert for Mar 2
Applied Optoelectronics, Inc. [AAOI] is up 21.71% over the past day.
Buy
90
BNAI alert for Mar 2
Brand Engagement Network, Inc. [BNAI] is up 2.44% over the past day.
Sell
36
WLDN alert for Mar 2
Willdan Group, Inc. [WLDN] is down 1.93% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
